Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.73 0.71 (5.91%) Market Cap: 558.63 Mil Enterprise Value: 452.90 Mil PE Ratio: 0 PB Ratio: 5.63 GF Score: 56/100

Y-mAbs Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 01:15AM GMT
Release Date Price: $7.53 (+4.87%)
Unidentified Participant

Good afternoon, everyone, and thank you for joining us here today. It is my pleasure to introduce Mike Rossi, President and CEO of Y-mAbs, who will be leading the presentation today; and Bo Kruse, CFO, will be joining Mike in the Q&A.

With that, I'll hand it over to Mike. Thank you, Mike, for joining us here today and sharing your story with us.

Michael Rossi
Y-mAbs Therapeutics Inc - President, Chief Executive Officer, Director

Thank you very much, and welcome to everyone. Thank you very much for attending our presentation of Y-mAbs Technologies -- Y-mAbs Therapeutics, excuse me. My name is Mike Rossi originally joined in November as the President of CEO. So I'm looking forward to taking you through our novel pre-targeted radiopharmaceutical platform, as well as our antibody-based therapy, DANYELZA. So thank you for attending.

As a disclaimer, please note that any of the forward-looking statements may be made today during our presentation and our disclaimer is available on our Investor Relations website.

So Y

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot